<DOC>
	<DOCNO>NCT02088073</DOCNO>
	<brief_summary>It hypothesize ZS effective placebo control ( alternative hypothesis ) maintain mean double-blind randomize maintenance phase ( DBRMP ) Day 8-29 serum potassium level ( 3.5 - 5.0 mmol/l , inclusive ) among hyperkalemic subject normokalemia establish open-label acute phase versus difference ZS dose ( high lowest ) versus placebo control ( null hypothesis ) .</brief_summary>
	<brief_title>Safety &amp; Efficacy Zirconium Silicate Dosed 28 Days Hyperkalemia .</brief_title>
	<detailed_description>Approximately 275 subject hyperkalemia ( two consecutive i-STAT potassium level ≥ 5.1 mmol/l , take 60 minute apart baseline ) enrol Open-label Acute Phase provide 232 subject Double Blind Randomized Maintenance Phase . Initially subject receive open-label ZS dose 10g three time day ( tid ) 48 hour ( AP ) . Subjects achieve normokalemia ( i-STAT potassium value 3.5 5.0 mmol/l , inclusive ) morning Study Day 3 ( 6 dose 10g ZS ) , double-blind fashion , randomize 4:4:4:7 receive one three dos ZS ( 5g , 10g 15g ) placebo control , qd follow 28 day ( DBRMP ) . Safety tolerability assess ongoing basis Independent Data Monitoring Committee ( iDMC ) . Each active dose group DBRMP consist 49 subject placebo control group consist 85 subject total 232 subject detect 0.6 effect size difference ZS dose ( high lowest ) placebo control ; 4:4:4:7 allocation optimize multiple comparison placebo control DBRMP .</detailed_description>
	<mesh_term>Hyperkalemia</mesh_term>
	<criteria>Provision write informed consent . Over 18 year age . Two consecutive iSTAT potassium value , measure 60minutes apart , ≥5.1 mmol/l measure within 1 day first ZS dose AP Study Day 1 . Ability repeat blood draw effective venous catheterization . Women childbearing potential must use two form medically acceptable contraception ( least one barrier method ) negative pregnancy test AP Study Day 1 . Women surgically sterile postmenopausal least 2 year consider childbearing potential . Pseudohyperkalemia sign symptom , excessive fist clench hemolyzed blood specimen , history severe leukocytosis thrombocytosis . Subjects treat lactulose , Xifaxan nonabsorbed antibiotic hyperammonemia within 7 day prior first dose study drug . Subjects treat resin ( sevelamer acetate sodium polystyrene sulfonate [ SPS ; e.g . Kayexalate® ] ) , calcium acetate , calcium carbonate , lanthanum carbonate , within 7 day prior first dose study drug . Subjects life expectancy le 3 month . Subjects severely physically mentally incapacitated opinion investigator unable perform subject ' task associate protocol . Women pregnant , lactating , plan become pregnant . Subjects diabetic ketoacidosis . Presence condition , opinion investigator , place subject undue risk potentially jeopardize quality data generate . Known hypersensitivity previous anaphylaxis ZS component thereof . Randomization previous ZS002 ZS003 study . Treatment drug device within last 30 day receive regulatory approval time study entry . Subjects cardiac arrhythmia require immediate treatment . Subjects dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>